Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China
Objective: To explore the prevalence and associated risk factors of early morning off (EMO) among outpatients with Parkinson’s disease (PD) in China. Background: PD is…An explorative study on the value of clinical features for diagnosing Parkinson’s disease
Objective: To investigate the usefulness of clinical features to differentiate subjects with “scans without evidence of dopaminergic deficit” (SWEDD) from patients presumed to have Parkinson’s…Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers.
Objective: To measure, with NM-MRI, the integrity of neuromelanin-containing monoaminergic cells in the SN and LC in Huntington Disease Gene Expansion Carriers (HDGECs) and compare…Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease
Objective: To explore grey-matter volume (GMV) differences between early-stage Huntington's disease (HD) patients with and without significant irritability/aggression symptoms (IAs) and to assess it association…Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)
Objective: Evaluate the change from baseline at week 52 in Q-Motor (Quantitative Motor) measures, exploratory, standardized, and rater-independent outcomes in the LEGATO-HD study. Background: LEGATO-HD…Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up
Objective: The objective of this study was to summarize evidence evaluating long-term (i.e. ≥ 12 months)efficacy of levodopa carbidopa intestinal gel (LCIG) on “off” time,…Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol
Objective: This study aims to assess feasibility of a herbal medication, HH368 for idiopathic Parkinson's disease (PD) patients who are in Hoehn & Yahr stage…Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 217
- Next Page »